surmount-osa trial tirzepatide results for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 Tirzepatide and Semaglutide: Impact on

When you begin tirzepatide , the active ingredient in Zepbound and Mounjaro , this personalized dosing approach is essential

Tirzepatide is an FDA-approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management

The most common adverse effects from the SURMOUNT trials include: Nausea: 24-33% of participants (dose-dependent) Diarrhea: 18-25% of participants Constipation: 13-17% of participants Vomiting: 8-12% of participants Decreased appetite: 10-15% of participants Most of these effects are mild to moderate and occur primarily during dose escalation periods

Tirzepatide activates two: GLP-1, which slows digestion and helps regulate appetite, and GIP, which influences how your body responds to insulin and stores energy

Combining the two amplifies certain side effects

Concentration variability Brand-name pens deliver a pre-measured dose